Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

Lithium Beats Valproate for Long-Term Bipolar Therapy

HealthDay News
by -- Randy Dotinga
Updated: Dec 23rd 2009

new article illustration

WEDNESDAY, Dec. 23 (HealthDay News) -- People with bipolar I disorder will do best over the long term with lithium treatment alone or a combination of lithium and valproate compared to valproate alone, new research suggests.

Patients who underwent the lithium or lithium/valproate treatments were less likely to relapse regardless of how severe their conditions were at the beginning of treatment, the study authors reported in the Dec. 22 online edition of The Lancet.

But the researchers couldn't say if the combined treatment is better or worse than lithium alone.

People with bipolar disorder have trouble regulating their moods and can swing between highs and lows. In most cases, patients have illness that is chronic or recurs over time. Doctors often prescribe combinations of drugs for these patients after single drugs fail to work, according to background information in a news release about the study.

The new study looked at 330 patients aged 16 and older with bipolar I disorder. The study participants lived in several countries, including the United States, and were randomly assigned to receive lithium, valproate or a combination of both drugs. They were followed for up to two years.

The results show that "for people with bipolar I disorder for whom long-term therapy is clinically indicated, combination therapy with lithium plus valproate is more likely to prevent relapse than is monotherapy with valproate. The 41 percent relative benefit is irrespective of baseline severity of illness, is maintained for up to two years, and is most apparent in prevention of manic relapse," the researchers concluded.

More information

The U.S. National Institute of Mental Health has more on bipolar disorder.




Family Service & Community Mental Health Center
4100 Veterans Parkway
McHenry, IL  60050 [map]

815-385-6400


powered by centersite dot net